All companies
Visit website
InnaMed (YC W17)
OperatingInnaMed, Inc.
Biotech · Founded 2016
Minority-founded
Using at-home blood testing technology to enable personalized medicine
Valuation cap ⓘ
$25.0M
As of May 2021 · from INNAMED SAFE 2 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$2,350,506
Across 2 rounds since 2019
Latest share price
$1.00
INNAMED SAFE 2 offering price
Financials
FY2017–FY2021 · from SEC filings · hover any figure for its source$0
−$424K
2017
$237K
−$475K
2018
$40K
−$414K
2019
$207K
−$282K
2020
$1.4M
−$2.0M
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2017
FY2018
FY2019
FY2020
FY2021
Income statement
Revenue
$0
$237,435
$40,000
$207,418
$1,439,995
Cost of goods sold
$0
$0
$0
$0
$0
Gross margin
—
100%
100%
100%
100%
Net income
-$424,383
-$474,753
-$414,407
-$282,354
-$1,951,729
Taxes paid
$0
$808
$0
$1,638
$4,024
Balance sheet
Cash
$393,754
$844,551
$80,049
$572,704
$1,051,262
Accounts receivable
$0
$0
$0
$150,000
$0
Total assets
$438,294
$882,560
$124,271
$819,936
$1,144,743
Short-term debt
$0
$3,426
$384
$196,705
$88
Long-term debt
$0
$0
$0
$30,000
$45,229
Total liabilities
$0
$3,426
$384
$226,705
$45,317
Other
Headcount
—
3
7
7
14
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$25.0M
Valuation cap
INNAMED SAFE 2
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $1.3M / $1.1MInvestors 1,407Valuation cap $25M
Raised $1.1M / $1.1MInvestors 2,440
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 2 of 7 annual reports (FY2019–FY2025)
2,440 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001773255Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.